These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. PET/CT for the staging and follow-up of patients with malignancies. Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595 [TBL] [Abstract][Full Text] [Related]
4. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers. Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792 [TBL] [Abstract][Full Text] [Related]
5. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle. Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129 [TBL] [Abstract][Full Text] [Related]
6. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
7. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study. Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803 [TBL] [Abstract][Full Text] [Related]
8. FDG PET/CT in the management of colorectal and anal cancers. Agarwal A; Marcus C; Xiao J; Nene P; Kachnic LA; Subramaniam RM AJR Am J Roentgenol; 2014 Nov; 203(5):1109-19. PubMed ID: 25341152 [TBL] [Abstract][Full Text] [Related]
9. The pivotal role of FDG-PET/CT in modern medicine. Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337 [TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT for staging of penile cancer. Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528 [TBL] [Abstract][Full Text] [Related]
11. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma? van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861 [TBL] [Abstract][Full Text] [Related]
12. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing central compartment neck dissection for squamous cell carcinoma of the larynx, hypopharynx, and esophagus. Kim JW; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY Oral Oncol; 2013 May; 49(5):449-53. PubMed ID: 23321549 [TBL] [Abstract][Full Text] [Related]
14. The role of 18F-FDG-PET and PET/CT in patients with sarcoidosis: an updated evidence-based review. Treglia G; Annunziata S; Sobic-Saranovic D; Bertagna F; Caldarella C; Giovanella L Acad Radiol; 2014 May; 21(5):675-84. PubMed ID: 24703482 [TBL] [Abstract][Full Text] [Related]
15. Value of retrospective image fusion of ¹⁸F-FDG PET and MRI for preoperative staging of head and neck cancer: comparison with PET/CT and contrast-enhanced neck MRI. Kanda T; Kitajima K; Suenaga Y; Konishi J; Sasaki R; Morimoto K; Saito M; Otsuki N; Nibu K; Sugimura K Eur J Radiol; 2013 Nov; 82(11):2005-10. PubMed ID: 23891295 [TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT of primary bone tumors. Costelloe CM; Chuang HH; Madewell JE AJR Am J Roentgenol; 2014 Jun; 202(6):W521-31. PubMed ID: 24848845 [TBL] [Abstract][Full Text] [Related]
17. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma. Qiu L; Chen Y; Wu J Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577 [TBL] [Abstract][Full Text] [Related]
18. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI. Chavdarova LI; Tzonevska AD; Piperkova EN Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584 [TBL] [Abstract][Full Text] [Related]
19. Role of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography in gastrointestinal cancers. Gauthé M; Richard-Molard M; Cacheux W; Michel P; Jouve JL; Mitry E; Alberini JL; Lièvre A; Dig Liver Dis; 2015 Jun; 47(6):443-54. PubMed ID: 25766918 [TBL] [Abstract][Full Text] [Related]
20. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Czernin J; Benz MR; Allen-Auerbach MS Eur J Radiol; 2010 Mar; 73(3):470-80. PubMed ID: 20097498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]